Inhibikase Therapeutics, Inc. (IKT) Q4 2024 Annual Earnings
IKT·Reported March 26, 2025·Before market open
Diluted EPS came in at $-0.63, missed the $-0.10 consensus by $0.53.
Diluted EPS
$-0.63missed by $0.53
Consensus: $-0.10
Financial Snapshot
Trailing eight quarters through Q4 2024
Q4 2024 Earnings FAQ
Common questions about Inhibikase Therapeutics, Inc.'s Q4 2024 earnings report.
Inhibikase Therapeutics, Inc. (IKT) reported Q4 2024 earnings on March 26, 2025 before market open.
Inhibikase Therapeutics, Inc. reported diluted EPS of $-0.63 for Q4 2024.
EPS missed the consensus estimate of $-0.10 by $0.53.
You can read the 10-K periodic report (0000950170-25-046096) directly on SEC EDGAR. The filing index links above go to sec.gov.